Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages

John W. Sleasman, Robert Nelson, Maureen M. Goodenow, David Wilfret, Alan Hutson, Michael Baseler, Judy Zuckerman, Philip A. Pizzo, Brigitta U. Mueller

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Objective: To evaluate lymphocyte reconstitution after protease inhibitor therapy in children with human immunodeficiency virus (HIV) infection. Study design: Forty-four HIV-infected children receiving ritonavir monotherapy followed by the addition of zidovudine and didanosine were evaluated during a phase I/II clinical trial. The cohort had a median age of 6.8 years and advanced disease (57% Centers for Disease Control and Prevention stage C, 73% immune stage 3) and was naive to protease inhibitor therapy. Results: After 4 weeks of therapy, there was a significant increase in CD4+ and CD8+ T cells. CD4+ T cells continued to increase, whereas CD8+ T cells returned to baseline by 24 weeks. Unexpectedly, there was a significant increase in B cells. Changes in CD4+ T-cell subsets revealed an initial increase in CD4+ CD45RO T cells followed by a sustained increase in CD4+ CD45RA T cells. Children <6 years of age had the highest increase in all lymphocyte populations. Significant improvement in CD4+ T-cell counts was observed even in those children whose viral burden returned to pretherapy levels. Conclusions: Early increases in lymphocytes after ritonavir therapy are a result of recirculation, as shown by increases in B cells and CD4+ CD45RO and CD8+ T cells. Children exhibited a high potential to reconstitute CD4+ CD45RA T cells even with advanced disease and incomplete viral suppression.

Original languageEnglish (US)
Pages (from-to)597-606
Number of pages10
JournalJournal of Pediatrics
Volume134
Issue number5
StatePublished - 1999
Externally publishedYes

Fingerprint

Ritonavir
Virus Diseases
HIV
Lymphocytes
T-Lymphocytes
Therapeutics
Protease Inhibitors
B-Lymphocytes
Didanosine
Phase II Clinical Trials
Clinical Trials, Phase I
Zidovudine
T-Lymphocyte Subsets
Centers for Disease Control and Prevention (U.S.)
CD4 Lymphocyte Count
Viral Load

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Sleasman, J. W., Nelson, R., Goodenow, M. M., Wilfret, D., Hutson, A., Baseler, M., ... Mueller, B. U. (1999). Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. Journal of Pediatrics, 134(5), 597-606.

Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. / Sleasman, John W.; Nelson, Robert; Goodenow, Maureen M.; Wilfret, David; Hutson, Alan; Baseler, Michael; Zuckerman, Judy; Pizzo, Philip A.; Mueller, Brigitta U.

In: Journal of Pediatrics, Vol. 134, No. 5, 1999, p. 597-606.

Research output: Contribution to journalArticle

Sleasman, JW, Nelson, R, Goodenow, MM, Wilfret, D, Hutson, A, Baseler, M, Zuckerman, J, Pizzo, PA & Mueller, BU 1999, 'Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages', Journal of Pediatrics, vol. 134, no. 5, pp. 597-606.
Sleasman, John W. ; Nelson, Robert ; Goodenow, Maureen M. ; Wilfret, David ; Hutson, Alan ; Baseler, Michael ; Zuckerman, Judy ; Pizzo, Philip A. ; Mueller, Brigitta U. / Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. In: Journal of Pediatrics. 1999 ; Vol. 134, No. 5. pp. 597-606.
@article{6b08c75a5e2540788eda748685b2f9c9,
title = "Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages",
abstract = "Objective: To evaluate lymphocyte reconstitution after protease inhibitor therapy in children with human immunodeficiency virus (HIV) infection. Study design: Forty-four HIV-infected children receiving ritonavir monotherapy followed by the addition of zidovudine and didanosine were evaluated during a phase I/II clinical trial. The cohort had a median age of 6.8 years and advanced disease (57{\%} Centers for Disease Control and Prevention stage C, 73{\%} immune stage 3) and was naive to protease inhibitor therapy. Results: After 4 weeks of therapy, there was a significant increase in CD4+ and CD8+ T cells. CD4+ T cells continued to increase, whereas CD8+ T cells returned to baseline by 24 weeks. Unexpectedly, there was a significant increase in B cells. Changes in CD4+ T-cell subsets revealed an initial increase in CD4+ CD45RO T cells followed by a sustained increase in CD4+ CD45RA T cells. Children <6 years of age had the highest increase in all lymphocyte populations. Significant improvement in CD4+ T-cell counts was observed even in those children whose viral burden returned to pretherapy levels. Conclusions: Early increases in lymphocytes after ritonavir therapy are a result of recirculation, as shown by increases in B cells and CD4+ CD45RO and CD8+ T cells. Children exhibited a high potential to reconstitute CD4+ CD45RA T cells even with advanced disease and incomplete viral suppression.",
author = "Sleasman, {John W.} and Robert Nelson and Goodenow, {Maureen M.} and David Wilfret and Alan Hutson and Michael Baseler and Judy Zuckerman and Pizzo, {Philip A.} and Mueller, {Brigitta U.}",
year = "1999",
language = "English (US)",
volume = "134",
pages = "597--606",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages

AU - Sleasman, John W.

AU - Nelson, Robert

AU - Goodenow, Maureen M.

AU - Wilfret, David

AU - Hutson, Alan

AU - Baseler, Michael

AU - Zuckerman, Judy

AU - Pizzo, Philip A.

AU - Mueller, Brigitta U.

PY - 1999

Y1 - 1999

N2 - Objective: To evaluate lymphocyte reconstitution after protease inhibitor therapy in children with human immunodeficiency virus (HIV) infection. Study design: Forty-four HIV-infected children receiving ritonavir monotherapy followed by the addition of zidovudine and didanosine were evaluated during a phase I/II clinical trial. The cohort had a median age of 6.8 years and advanced disease (57% Centers for Disease Control and Prevention stage C, 73% immune stage 3) and was naive to protease inhibitor therapy. Results: After 4 weeks of therapy, there was a significant increase in CD4+ and CD8+ T cells. CD4+ T cells continued to increase, whereas CD8+ T cells returned to baseline by 24 weeks. Unexpectedly, there was a significant increase in B cells. Changes in CD4+ T-cell subsets revealed an initial increase in CD4+ CD45RO T cells followed by a sustained increase in CD4+ CD45RA T cells. Children <6 years of age had the highest increase in all lymphocyte populations. Significant improvement in CD4+ T-cell counts was observed even in those children whose viral burden returned to pretherapy levels. Conclusions: Early increases in lymphocytes after ritonavir therapy are a result of recirculation, as shown by increases in B cells and CD4+ CD45RO and CD8+ T cells. Children exhibited a high potential to reconstitute CD4+ CD45RA T cells even with advanced disease and incomplete viral suppression.

AB - Objective: To evaluate lymphocyte reconstitution after protease inhibitor therapy in children with human immunodeficiency virus (HIV) infection. Study design: Forty-four HIV-infected children receiving ritonavir monotherapy followed by the addition of zidovudine and didanosine were evaluated during a phase I/II clinical trial. The cohort had a median age of 6.8 years and advanced disease (57% Centers for Disease Control and Prevention stage C, 73% immune stage 3) and was naive to protease inhibitor therapy. Results: After 4 weeks of therapy, there was a significant increase in CD4+ and CD8+ T cells. CD4+ T cells continued to increase, whereas CD8+ T cells returned to baseline by 24 weeks. Unexpectedly, there was a significant increase in B cells. Changes in CD4+ T-cell subsets revealed an initial increase in CD4+ CD45RO T cells followed by a sustained increase in CD4+ CD45RA T cells. Children <6 years of age had the highest increase in all lymphocyte populations. Significant improvement in CD4+ T-cell counts was observed even in those children whose viral burden returned to pretherapy levels. Conclusions: Early increases in lymphocytes after ritonavir therapy are a result of recirculation, as shown by increases in B cells and CD4+ CD45RO and CD8+ T cells. Children exhibited a high potential to reconstitute CD4+ CD45RA T cells even with advanced disease and incomplete viral suppression.

UR - http://www.scopus.com/inward/record.url?scp=0033497379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033497379&partnerID=8YFLogxK

M3 - Article

VL - 134

SP - 597

EP - 606

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 5

ER -